CORT Company Profile and Key Details

Q: Who are the executives of CORT?

Dr. William Guyer Pharm.D.Chief Devel. OfficerDr. Hazel Hunt Ph.D.Chief Scientific OfficerDr. Joseph K. Belanoff M.D.Co-Founder, Pres, Chief Executive Officer & DirectorMr. Joseph Douglas LyonChief Accounting OfficerMr. Sean MaduckPres of Corcept EndocrinologyMs. Amy FloodChief HR & Communications OfficerMr. Atabak MokariChief Financial Officer & TreasurerMr. Gary Charles RobbChief Bus. Officer & Sec.

NASDAQ : CORT

Corcept Therapeutics

$33.51

1.33+4.13%

At Close 4:00 PM

53.74

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Corcept Therapeutics Incorporated (CORT) stock surged +4.13%, trading at $33.51 on NASDAQ, up from the previous close of $32.18. The stock opened at $32.41, fluctuating between $32.23 and $33.68 in the recent session.

Stock Snapshot

32.18

Prev. Close

3.56B

Market Cap

32.23

Day Low

40.87

P/E Ratio

0.82

EPS (TTM)

1.24

Cash Flow per Share

32.41

Open

106.37M

Number of Shares

33.68

Day High

82.48%

Free Float in %

4.95

Book Value

922.15K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 17, 2026	32.41	33.68	32.23	33.51	1.03M
Mar 16, 2026	32.36	32.85	32.04	32.18	725.01K
Mar 13, 2026	32.77	33.12	31.81	32.15	1.02M
Mar 12, 2026	33.22	33.43	31.96	32.39	1.14M
Mar 11, 2026	33.47	34.27	33.00	33.74	1.23M
Mar 10, 2026	34.00	34.00	32.93	33.54	965.42K
Mar 09, 2026	33.57	34.11	33.10	33.99	1.2M
Mar 06, 2026	33.26	34.18	33.00	33.87	1.17M
Mar 03, 2026	34.92	35.73	33.99	35.28	1.38M
Mar 02, 2026	34.56	36.27	34.34	35.97	1.13M
Feb 27, 2026	35.21	35.74	34.57	35.70	1.38M
Feb 26, 2026	36.47	36.47	34.50	35.78	1.57M
Feb 25, 2026	37.65	38.22	33.94	36.22	2.96M
Feb 24, 2026	35.40	37.58	35.40	36.48	1.94M
Feb 23, 2026	34.61	35.78	34.21	35.34	1.66M
Feb 20, 2026	33.97	35.06	33.29	34.82	2.53M
Feb 19, 2026	39.65	40.28	28.66	34.24	11.71M
Feb 18, 2026	39.48	40.51	39.15	39.82	807.96K
Feb 17, 2026	39.90	40.41	39.41	39.63	840.21K
Feb 13, 2026	39.11	40.43	39.09	39.97	641.42K

Contact Details

Menlo Park, CA 94025

United States

https://www.corcept.com 650 327 3270

About Company

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Stock Peers

REGN

2.14+0.28%

Regeneron Pharmaceuticals, Inc.$759.05 ARGX

2.73+0.39%

argenx SE$706.03 UTHR

5.72001+1.07%

United Therapeutics Corporation$540.02 VRTX

-3.61-0.77%

Vertex Pharmaceuticals Incorporated$462.49 MDGL

2.35+0.53%

Madrigal Pharmaceuticals, Inc.$443.18 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.51+0.47%

Alnylam Pharmaceuticals, Inc.$320.42 PRAX

-1.62-0.53%

Praxis Precision Medicines, Inc.$303.38 KRYS

6.17+2.47%

Krystal Biotech, Inc.$256.33 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Corcept Therapeutics Incorporated (NASDAQ:CORT) closed at $33.51 USD, gaining $1.33 (4.13%) from the previous close of $32.18. The stock is currently mid-range between its 52-week high and low $28.66 and $117.33. With a market capitalization of about $3.56 billion, Corcept Therapeutics Incorporated is classified as a mid-cap and shows lower-than-market volatility (beta ~0.31). Key stats such as the average daily volume over the past year has been around 2.27 million shares, volume is running light vs its 52-week average. Headquartered in Menlo Park, CA, Corcept Therapeutics Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joseph K. Belanoff, the company employs approximately 500 people and listed since April 14, 2004. Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -8.13%, SMA50 -25.72%, SMA200 -47.47%). The stock’s 14-day RSI is 36.73 (weak momentum), while the ATR of 2.96 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -69.5% below its high and over 24.84% above its low. Average 10-day trading volume of 1.04 million shares is below the 3-month average of 2.28 million, indicating normal recent market interest.

Valuation Metrics

Corcept Therapeutics Incorporated trades at a P/E ratio of 34.85, slightly above the S&P 500 average, with a price-to-sales ratio of 4.64 and a price-to-book ratio of 5.33 trading at moderately above to book value. The P/FCF stands at 24.94, also above market averages.

Dividend & Fair Value

Corcept Therapeutics Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $246.92. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Corcept Therapeutics Incorporated generated EPS of $0.82 over the past year. Five-year average earnings growth is -0.84%. Wall Street analysts project EPS growth of 51.72% annually over the next five years. The latest quarter delivered EPS of $0.16. The next quarter is forecast at -$0.10. Next year's EPS is expected at $2.37. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 15 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $150.00 to $67.00. The high target offers 347.63% upside. The low target suggests 99.94% downside. The mean target is $127.94. This offers 281.8% upside. Corcept Therapeutics Incorporated earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by -11.11%. The prior quarter beat by 26.09%. Over the last six quarters, Apple has recorded several small beats. These include 39.13% in July 29, 2024.

Shareholding & Insider Activity

Corcept Therapeutics Incorporated has 105.37 million shares outstanding. The public float is 86.91 million shares, elevated short interest at 13.95% of float. This equals 10.88 million shares. The short ratio is 13.35 days. Institutional investors hold 85.94% of the float. Insiders own 11.55%. BELANOFF JOSEPH K holds 2.70 million shares, BAKER G LEONARD JR has 1.05 million shares and Hunt Hazel has 73.15 thousand shares. Over the past six months, insider transactions show net selling. They sold 187.12 thousand shares across 18 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Corcept Therapeutics generated $482.38M in revenue, or $4.32 per share. Gross margin was 98.66%, operating margin 22.24%, and net profit margin 22.00%. Returns are exceptional, with ROA at 17.08% and ROE at 20.95%.
On valuation metrics, Corcept Therapeutics trades at a P/E of 34.85, P/S of 4.64 and P/B of 5.33. The current ratio is 2.92 and quick ratio is 2.85. Operationally, the company’s inventory turnover is 1.01 and cash conversion cycle is -746.96 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of 23.25.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Corcept Therapeutics posted revenue of $482.38M, down slightly from $401.86M in the prior quarter. Gross profit was $475.89M (margin 98.66%). Operating income was $107.28M (margin 22.2%). Net income was$106.14M (EPS $1.02).
The company ended the quarter with $368.22M in cash and short-term investments, a total debt of $151.00K, and net debt of - $135.40M. Total assets were $621.52M, with equity of $506.71M. Financials further reflected stability, with operating cash flow of $127.04M, free cash flow of $126.90M, and capital expenditures of - $139.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Corcept Therapeutics Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.13%, with price expected at $29.78 by March 31, 2026, within a range of $28.32 to $31.33 3-Month Outlook: Projected rise of 68.93%, reaching $56.61 by June 15, 2026, with a range of $51.27 to $61.59. 1-Year Outlook: Projected gain of 57.59%, with price at $52.81 by March 17, 2027, within a range of $48.08 to $57.17.

Key Takeaways

Corcept Therapeutics Incorporated (NASDAQ:CORT) shares are flat 1.41% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Corcept Therapeutics Incorporated trading at a premium to the broader market with a P/E of 34.85. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $63.93, suggesting 90.78% upside. Our AI forecast model points to short-term weakness (-11.13% over two weeks), a medium-term rise (68.93% over three months), and a longer-term gain (57.59% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Corcept Therapeutics Incorporated (CORT) stock price?

Corcept Therapeutics Incorporated (NASDAQ: CORT) stock price is $33.51 in the last trading session. During the trading session, CORT stock reached the peak price of $33.68 while $32.23 was the lowest point it dropped to. The percentage change in CORT stock occurred in the recent session was 4.13% while the dollar amount for the price change in CORT stock was $1.33.

CORT's industry and sector of operation?

The NASDAQ listed CORT is part of Biotechnology industry that operates in the broader Healthcare sector. Corcept Therapeutics Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CORT?

Dr. William Guyer Pharm.D.
Chief Devel. Officer
Dr. Hazel Hunt Ph.D.
Chief Scientific Officer
Dr. Joseph K. Belanoff M.D.
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Joseph Douglas Lyon
Chief Accounting Officer
Mr. Sean Maduck
Pres of Corcept Endocrinology
Ms. Amy Flood
Chief HR & Communications Officer
Mr. Atabak Mokari
Chief Financial Officer & Treasurer
Mr. Gary Charles Robb
Chief Bus. Officer & Sec.

How CORT did perform over past 52-week?

CORT's closing price is 16.92% higher than its 52-week low of $28.66 where as its distance from 52-week high of $117.33 is -71.44%.

How many employees does CORT have?

Number of CORT employees currently stands at 500.

Link for CORT official website?

Official Website of CORT is: https://www.corcept.com

How do I contact CORT?

CORT could be contacted at phone 650 327 3270 and can also be accessed through its website. CORT operates from 149 Commonwealth Drive, Menlo Park, CA 94025, United States.

How many shares of CORT are traded daily?

CORT stock volume for the day was 922.15K shares. The average number of CORT shares traded daily for last 3 months was 2.27M.

What is the market cap of CORT currently?

The market value of CORT currently stands at $3.56B with its latest stock price at $33.51 and 106.37M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	500
Beta	0.31
Sales or Revenue	$482.38M
5Y Sales Change%	1.33%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CORT Company Profile and Key Details

Corcept Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics